Skip to main content
Premium Trial:

Request an Annual Quote

Horizon Licenses Gene Engineering Technology from University of Washington

NEW YORK (GenomeWeb News) – Horizon Discovery said this week that it has licensed exclusive worldwide rights from the University of Washington to a gene engineering technology that is used as part of its Genesis platform.
The Cambridge, UK-based firm said that the Genesis platform is used to create patient-relevant disease models, called X-Man cell lines. The firm has developed more than 100 of these cell models that are intended to help drug researchers understand how cancer manifests itself in real patients and to help in the development of personalized therapeutics, diagnostics, and theranostic tests.
The viral-based gene engineering technology is “absolutely essential to generating X-Man lines efficiently and reproducibly,” the firm said in a statement.
“In 2009, we will disseminate our technology (and the products and services based upon it) to all levels of academic, industrial and clinical research and begin the process of co-opting the support of healthcare and political leaders; critical in implementing changes in how personalized treatments are discovered and administered," said Horizon Discovery CEO Chris Torrance.
Terms of the license were not disclosed.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.